Biomarkers and methods for predicting preterm birth
AssigneeSera Prognostics, Inc.
InventorsDurlin Edward Hickok, John Jay Boniface, Gregory Charles Critchfield, Tracey Cristine Fleischer
Life of this patent
Estimating the term…
Loading patent…
AssigneeSera Prognostics, Inc.
InventorsDurlin Edward Hickok, John Jay Boniface, Gregory Charles Critchfield, Tracey Cristine Fleischer
Estimating the term…
The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexpected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers.
A method of determining probability for preterm birth in a pregnant female, the method comprising detecting a level of disintegrin and metalloproteinase domain-containing protein 12 (ADA12) in a biological sample obtained from said pregnant female,
A method of predicting gestational age at birth (GAB), the method comprising detecting a level of disintegrin and metalloproteinase domain-containing protein 12 (ADA12) in a biological sample obtained from a pregnant female, analyzing said level to predict GAB, calculating a risk score for ADA12 using gestational age matched controls as a reference, wherein the calculated risk score for ADA12 corresponds to a probability of GAB being (i) less than 37 weeks, (ii) 37 to 39 weeks, or (iii) 40 weeks or greater, and administering a prenatal intervention to the pregnant female when the GAB is predicted to be less than 37 weeks,
Dependencies are inferred from the claim text.